Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.

Abstract excerpt

The small-molecule inhibitor lenacapavir (LEN) has firmly established the HIV-1 capsid as a promising clinical target. However, early studies have shown that HIV-1 can develop resistance to LEN by acquiring capsid mutations. These mutations are restricted to the drug-binding pocket, but the breadth of the virus's capacity to evolve under LEN-directed pressure remains incompletely understood. Here, we employ an...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acetamides
• Share to Anti-HIV Agents